Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840090 | 0.87 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2HPGDPOLBHTT | |
| SCHEMBL29522198 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2HPGDPOLBMEN1 | |
| SCHEMBL1677059 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2HPGDPOLBMEN1 | |
| SCHEMBL4509115 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDPOLBHTT | |
| SCHEMBL2858017 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDPOLBHTT | |
| SCHEMBL8008330 | 0.84 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2HPGDPOLBHTT | |
| SCHEMBL1879618 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HPGDHTTFKBP1A | |
| SCHEMBL9659992 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HPGDPOLBHTT | |
| SCHEMBL11705518 | 0.83 | CA1 (0.71) | ALDH1A1SMN1; SMN2HPGDPOLBKMT2A | |
| SCHEMBL29582937 | 0.83 | POLB (1.00) | ALDH1A1SMN1; SMN2HPGDPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIV KANSAS (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-107922362-B | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-06-15 | — | — | CN | disclosed |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | UNIVERSITY OF KANSAS (US) | 2020-12-15 | — | — | US | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS | 2018-10-04 | — | — | US | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| EP-3328843-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| US-5693804-A | USEFUL IN TREATING NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS AND ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0792269-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5658909-A | INHIBITION OF ABNORMALLY PHOSPHORYLATED PAIRED HELICAL FILAMENT EPITOPE FORMATION | MOLECULAR GERIATRICS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996015792-A9 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | — | 1996-09-12 | — | — | WO | disclosed |
| WO-1996016052-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5155268-A | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides | THE UPJOHN COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0164865-B1 | N-(AMINOALKYLPHENYL)SULFONAMIDES THEIR PREPARATION AND THERAPEUTIC USE | THE UPJOHN COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| EP-0164865-A1 | N-(Aminoalkylphenyl)sulfonamides their preparation and therapeutic use | THE UPJOHN COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | ALDH1A1 176/4885SMN1; SMN2 1602/4885HPGD 534/4885 |
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | ALDH1A1 3811/4885SMN1; SMN2 3138/4885HPGD 651/4885 |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | ALDH1A1 3811/4885SMN1; SMN2 3138/4885HPGD 651/4885 |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | ALDH1A1 3811/4885SMN1; SMN2 3138/4885HPGD 651/4885 |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | MTCH2, TIMM50, TIMM10 | ALDH1A1 3811/4885SMN1; SMN2 3138/4885HPGD 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.